Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis

Abstract Background Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive disease that makes up about 20% of all invasive breast cancers. HER2+ breast cancer is associated with poor prognosis and high mortality rates, but the development of HER2-targeted therapies,...

Full description

Bibliographic Details
Main Authors: Florence R. Wilson, Megan E. Coombes, Quinlan Wylie, Mariya Yurchenko, Christine Brezden-Masley, Brian Hutton, Becky Skidmore, Chris Cameron
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Systematic Reviews
Subjects:
Early breast cancer
HER2-positive breast cancer
Herceptin®
Targeted therapy
Trastuzumab
Survival
Online Access:http://link.springer.com/article/10.1186/s13643-017-0588-2

Internet

http://link.springer.com/article/10.1186/s13643-017-0588-2

Similar Items